The present invention relates inter alia to expression vector production as well as application to the production of host cells for protein repertoire expression and high-throughput screening. The invention also relates to primers useful for PCR amplification of nucleotide sequences encoding human antibody variable domains.

The present invention relates inter alia to expression vector production as well as application to the production of host cells for protein repertoire expression and high-throughput screening. The invention also relates to primers useful for PCR amplification of nucleotide sequences encoding human antibody variable domains.

This disclosure describes methods and compositions for detecting the presence of autoantibodies associated with autoimmune polyglandualar syndrome 1 (APS1) in a biological sample. In particular, detection of APS1-specific autoantibodies that specifically bind to certain APS1 associated autoantigens in such methods is described. Also provided are methods of treating subjects with APS1 or at risk of developing APS1 associated conditions. Also provided are devices and kits useful for the diagnosis and prognostic assessment of subjects having APS1 and for assessing subject risk at developing particular APS1-associated conditions.

This disclosure describes methods and compositions for detecting the presence of autoantibodies associated with autoimmune polyglandualar syndrome 1 (APS1) in a biological sample. In particular, detection of APS1-specific autoantibodies that specifically bind to certain APS1 associated autoantigens in such methods is described. Also provided are methods of treating subjects with APS1 or at risk of developing APS1 associated conditions. Also provided are devices and kits useful for the diagnosis and prognostic assessment of subjects having APS1 and for assessing subject risk at developing particular APS1-associated conditions.

The present application relates to recombinant antibodies that are engineered to alter interactions between the antibodies and one or more endogenous lipases of a host cell used to produce the antibodies. In some cases, the antibodies are mutated in the heavy chain constant region, such as at CH1, CH2, and/or CH3. In other cases, the antibodies are mutated to alter their glycosylation profile.

Methods and apparatuses (e.g., systems, devices, etc.) for delivering a nebulized drug agent in the nasal passages concurrent with the lungs.

Methods and apparatuses (e.g., systems, devices, etc.) for delivering a nebulized drug agent in the nasal passages concurrent with the lungs.

This invention relates to a method of selecting a collection of frame-shift peptides (CFSPs) to produce a universal cancer vaccine peptide collection (CVP) for prophylaxis and treatment of patients with hereditary and sporadic micro-satellite instability (MSI) tumors. This invention relates as well to a method of producing a CVP by selecting a subset of frame-shift peptides (FSPs) from the CFSP and optionally modifying the FSP's amino acid (aa) sequence to generate modified FSPs (mFSPs). The invention further relates to nucleic acid collections encoding a CVP of FSPs and/or mFSPs in one or more vaccine vectors that can be used also simultaneously. These CVPs, nucleic acids and vectors are used for the prophylaxis or treatment of MSI cancers.

It is an object of the present invention to provide a method for efficiently producing a B cell population comprising B cells that recognize a specific antigen. According to the present invention, provided is a method for producing a B cell population, comprising: a step (c) of culturing a cell population comprising B cells together with a specific antigen in the absence of IL-21, in the absence of IL-4, and in the presence of a cytokine other than IL-21 and IL-4, while giving stimulation mediated by CD40 and a BAFF receptor to the cells; and a step (d) of culturing the cell population comprising B cells, while giving stimulation mediated by has to the cells, so as to obtain a B cell population comprising B cells that recognize the specific antigen.

Provided herein are libraries containing polynucleotides, where one of the polynucleotides encodes an antibody heavy chain with specific hypervariable regions HVR-H1 and HVR-H2. Further provided herein are libraries containing polynucleotides encoding a plurality of unique antibodies, wherein each antibody comprises a heavy chain variable region and a light chain variable region. Also provided are antibodies, polypeptide libraries, vector libraries, cells, non-human animals, antibody heavy chains, methods of making an antibody library, kits, and methods of generating a bispecific antibody related thereto.